ruxolitinib - versus vitamin C - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.15 [0.01, 3.29]< 10%1 study (1/-)88.2 %NAnot evaluable crucial-
clinical deterioration 0.11 [0.01, 2.21]< 10%1 study (1/-)92.3 %NAnot evaluable important-
clinical improvement 1.67 [0.84, 3.33]> 10%1 study (1/-)92.7 %NAnot evaluable important-
clinical improvement (14-day) 2.00 [0.58, 6.94]> 10%1 study (1/-)86.2 %NAnot evaluable important-
clinical improvement (21-day) 1.50 [0.22, 10.08]> 10%1 study (1/-)66.1 %NAnot evaluable important-
clinical improvement (7-day) 2.38 [0.38, 14.70]> 10%1 study (1/-)82.3 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.67 [0.84, 3.33]> 10%1 study (1/-)92.7 %NAnot evaluable important-
radiologic improvement (14-day) 5.54 [1.01, 30.50]> 10%1 study (1/-)97.5 %NAnot evaluable important-

safety endpoints 00

serious adverse events 0.11 [0.01, 2.21]< 10%1 study (1/-)92.3 %NAnot evaluable important-
adverse events 1.60 [0.38, 6.81]< 10%1 study (1/-)26.3 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.